Umoja Biopharma

Umoja Biopharma is a Seattle-based clinical-stage immuno-oncology company developing in vivo CAR T cell therapies for cancer. Its VivoVec lentiviral platform generates CAR T cells directly in a patient's body, removing the ex vivo manufacturing step of traditional cell therapy, and the company operates its own manufacturing facility in Louisville, Colorado. Its pipeline includes UB-VV111 (CD19), UB-VV400 (the industry's first known CD22-directed in vivo CAR T candidate, FDA IND clearance July 2026), and UB-VV500. Umoja is backed by investors including DCVC (DCVC Bio) and SoftBank Vision Fund 2. The company publishes no public developer API, OpenAPI, or developer portal; this profile captures the company identity and the security posture of its public web surface.

Umoja Biopharma is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Immunotherapy, CAR-T, and Cell Therapy.

Umoja Biopharma’s developer surface includes engineering blog and 9 more developer resources.

🌐 Visit website 📡 Source on GitHub

11.2/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5

0 APIs

CompanyBiotechnologyImmunotherapyCAR-TCell TherapyOncologyGene TherapyHealthcare

Kin Score

Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5

Composite quality — 11.2/100 · minimal

Contract Quality 0.0 / 25

Developer Ergonomics 0.4 / 20

Commercial Clarity 2.1 / 20

Operational Transparency 0.0 / 13

Governance 0.0 / 12

Discoverability 6.8 / 10

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 15

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/umoja: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Operate 1

Status, limits, changes, and where to get help

Contact

Contact

Commercial 1

Pricing, plans, and the legal terms of use

PrivacyPolicy

PrivacyPolicy

Company 7

The organization behind the API

Website

About

Blog

BlogRSS

Careers

LinkedIn

Twitter

Twitter

Scroll for all 7

Source (apis.yml)

aid: umoja
name: Umoja Biopharma
description: Umoja Biopharma is a Seattle-based clinical-stage immuno-oncology company developing in vivo CAR T cell therapies
  for cancer. Its VivoVec lentiviral platform generates CAR T cells directly in a patient's body, removing the ex vivo manufacturing
  step of traditional cell therapy, and the company operates its own manufacturing facility in Louisville, Colorado. Its pipeline
  includes UB-VV111 (CD19), UB-VV400 (the industry's first known CD22-directed in vivo CAR T candidate, FDA IND clearance
  July 2026), and UB-VV500. Umoja is backed by investors including DCVC (DCVC Bio) and SoftBank Vision Fund 2. The company
  publishes no public developer API, OpenAPI, or developer portal; this profile captures the company identity and the security
  posture of its public web surface.
url: https://raw.githubusercontent.com/api-evangelist/umoja/refs/heads/main/apis.yml
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://www.umoja-biopharma.com/wp-content/uploads/2022/08/UMOJA_Facebook.png
x-type: company
x-source: vc-portfolio
x-backed-by:
- dcvc
- softbank-vision-fund
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-21'
tags:
- Company
- Biotechnology
- Immunotherapy
- CAR-T
- Cell Therapy
- Oncology
- Gene Therapy
- Healthcare
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/umoja-domain-security.yml
- type: Website
  url: https://www.umoja-biopharma.com/
- type: About
  url: https://www.umoja-biopharma.com/our-company/
- type: Blog
  url: https://www.umoja-biopharma.com/news/
- type: BlogRSS
  url: https://www.umoja-biopharma.com/feed/
- type: PrivacyPolicy
  url: https://www.umoja-biopharma.com/privacy-policy/
- type: Contact
  url: https://www.umoja-biopharma.com/contact/
- type: Careers
  url: https://www.umoja-biopharma.com/careers/
- type: LinkedIn
  url: https://www.linkedin.com/company/umoja-biopharma/
- type: Twitter
  url: https://twitter.com/UmojaBiopharma
x-enrichment:
  date: '2026-07-21'
  status: minimal
  artifacts_added: 1
  pass: local-v1